AST 021p
Alternative Names: AST-021pLatest Information Update: 28 Jul 2024
At a glance
- Originator Korea University
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
- Mechanism of Action Immunostimulants; Th1 cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Recurrent) in South Korea (Intradermal)
- 05 Apr 2024 Adverse events data from a phase I CornerStone-002 trial in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 05 Apr 2024 Pharmacodynamics data from the preclinical studies in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)